Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac).
about
Resting blood flow in the skin: does it exist, and what is the influence of temperature, aging, and diabetes?Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic RetinopathyGlycobiology of ocular angiogenesis.Development of a miR-92a delivery system for anti-angiogenesis-based cancer therapy.Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration.Ligand-functionalized nanoparticles target endothelial cells in retinal capillaries after systemic application.Nrf2 acts cell-autonomously in endothelium to regulate tip cell formation and vascular branching.Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin.Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathyNrf2 in ischemic neurons promotes retinal vascular regeneration through regulation of semaphorin 6A.In vitro and ex vivo retina angiogenesis assays.Thyroid hormone and anti-apoptosis in tumor cells.Nongenomic actions of thyroid hormone.Thyroid Hormone, Hormone Analogs, and Angiogenesis.Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.Relationship between Pericytes and Endothelial Cells in Retinal Neovascularization: A Histological and Immunofluorescent Study of Retinal Angiogenesis.Collective adhesion and displacement of retinal progenitor cells upon extracellular matrix substrates of transplantable biomaterials.Retinal and choroidal angiogenesis: a review of new targets.
P2860
Q26998382-A6C59850-AFA6-4C02-8C81-D5CCB157D8DBQ28078199-DFD6A954-C8D1-44E6-818D-D0292F0F1F11Q34414227-2DF48C75-654D-41FA-BF1E-8AFCE226F03EQ34512023-0892D79F-1E57-4C57-A068-4B4A6F5F9BE9Q34555545-6F08F79E-21D2-41F1-99FF-D25C99C24D80Q34636224-F3D969EC-361F-4E19-A958-88FB340265B8Q34996091-4699DEEE-1426-4C17-AE74-1AC0FB8BE0CFQ35587285-967B3EE9-7B50-4D82-A5EA-4539958750CEQ36379513-56879D02-B3AD-4D59-A59D-5E787E95BC7CQ36394244-27371DFA-79CE-4DA8-8224-9FBF3F6B4671Q38152261-E10F647C-ECF2-4C8F-A6FB-6EA5C7FA0271Q38515254-E611A4A5-90D2-464C-8DE1-85F3D804B174Q38669510-FDAE0CEB-6C16-49FC-8DF2-62C8961F7AA3Q38693285-5D425138-C031-4AFA-B7A9-8328A877FD73Q38987118-A3873651-A2B3-438B-9DF2-C848149D0639Q47708166-9F3A85D7-BD03-4F8E-AA82-CDFC0105EE7CQ48222695-CE92287F-6262-4375-BD5B-52E08AC6A203Q53098522-53481D90-90BF-4339-93DE-4D12CA572F0C
P2860
Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac).
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Inhibition of pathological ret ...... iodothyroacetic acid (tetrac).
@en
type
label
Inhibition of pathological ret ...... iodothyroacetic acid (tetrac).
@en
prefLabel
Inhibition of pathological ret ...... iodothyroacetic acid (tetrac).
@en
P2093
P2860
P1476
Inhibition of pathological ret ...... iodothyroacetic acid (tetrac).
@en
P2093
Elia J Duh
Junsong Gong
Takeshi Yoshida
Yanhong Wei
Zhenhua Xu
P2860
P356
10.1016/J.EXER.2011.11.003
P577
2011-11-19T00:00:00Z